Bitsika V - Search Results

1

Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure.

Zagoura DS, Roubelakis MG, Bitsika V, Trohatou O, Pappa KI, Kapelouzou A, Antsaklis A, Anagnou NP. Zagoura DS, et al. Among authors: bitsika v. Gut. 2012 Jun;61(6):894-906. doi: 10.1136/gutjnl-2011-300908. Epub 2011 Oct 13. Gut. 2012. PMID: 21997562

2

AF-MSCs fate can be regulated by culture conditions.

Zagoura DS, Trohatou O, Bitsika V, Makridakis M, Pappa KI, Vlahou A, Roubelakis MG, Anagnou NP. Zagoura DS, et al. Among authors: bitsika v. Cell Death Dis. 2013 Apr 4;4(4):e571. doi: 10.1038/cddis.2013.93. Cell Death Dis. 2013. PMID: 23559005 Free PMC article.

3

Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells.

Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, Vlahou A, Papadaki HA, Antsaklis A, Anagnou NP. Roubelakis MG, et al. Among authors: bitsika v. Stem Cells Dev. 2007 Dec;16(6):931-52. doi: 10.1089/scd.2007.0036. Stem Cells Dev. 2007. PMID: 18047393

4

In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells.

Roubelakis MG, Bitsika V, Zagoura D, Trohatou O, Pappa KI, Makridakis M, Antsaklis A, Vlahou A, Anagnou NP. Roubelakis MG, et al. Among authors: bitsika v. J Cell Mol Med. 2011 Sep;15(9):1896-913. doi: 10.1111/j.1582-4934.2010.01180.x. J Cell Mol Med. 2011. PMID: 21166769 Free PMC article.

5

Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: a novel approach for the treatment of bladder cancer.

Bitsika V, Roubelakis MG, Zagoura D, Trohatou O, Makridakis M, Pappa KI, Marini FC, Vlahou A, Anagnou NP. Bitsika V, et al. Stem Cells Dev. 2012 May 1;21(7):1097-111. doi: 10.1089/scd.2011.0151. Epub 2011 Oct 11. Stem Cells Dev. 2012. PMID: 21988169

6

Fetal mesenchymal stem cells in cancer therapy.

Bitsika V, Vlahou A, Roubelakis MG. Bitsika V, et al. Curr Stem Cell Res Ther. 2013 Mar;8(2):133-43. doi: 10.2174/1574888x11308020004. Curr Stem Cell Res Ther. 2013. PMID: 23176305 Review.

7

Sox2 suppression by miR-21 governs human mesenchymal stem cell properties.

Trohatou O, Zagoura D, Bitsika V, Pappa KI, Antsaklis A, Anagnou NP, Roubelakis MG. Trohatou O, et al. Among authors: bitsika v. Stem Cells Transl Med. 2014 Jan;3(1):54-68. doi: 10.5966/sctm.2013-0081. Epub 2013 Dec 4. Stem Cells Transl Med. 2014. PMID: 24307698 Free PMC article.

8

Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer.

Makridakis M, Gagos S, Petrolekas A, Roubelakis MG, Bitsika V, Stravodimos K, Pavlakis K, Anagnou NP, Coleman J, Vlahou A. Makridakis M, et al. Among authors: bitsika v. Proteomics. 2009 Jan;9(2):287-98. doi: 10.1002/pmic.200800121. Proteomics. 2009. PMID: 19105184

9

Analysis of secreted proteins for the study of bladder cancer cell aggressiveness.

Makridakis M, Roubelakis MG, Bitsika V, Dimuccio V, Samiotaki M, Kossida S, Panayotou G, Coleman J, Candiano G, Anagnou NP, Vlahou A. Makridakis M, et al. Among authors: bitsika v. J Proteome Res. 2010 Jun 4;9(6):3243-59. doi: 10.1021/pr100189d. J Proteome Res. 2010. PMID: 20423150

10

Profilin 1 is a potential biomarker for bladder cancer aggressiveness.

Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, Stravodimos K, Anagnou NP, Roubelakis MG, Sanchez-Carbayo M, Vlahou A. Zoidakis J, et al. Among authors: bitsika v. Mol Cell Proteomics. 2012 Apr;11(4):M111.009449. doi: 10.1074/mcp.M111.009449. Epub 2011 Dec 8. Mol Cell Proteomics. 2012. PMID: 22159600 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters